<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307396</url>
  </required_header>
  <id_info>
    <org_study_id>1723/1-1</org_study_id>
    <secondary_id>2013-000338-37</secondary_id>
    <secondary_id>DO 1723/1-1</secondary_id>
    <secondary_id>DRKS00006878</secondary_id>
    <nct_id>NCT02307396</nct_id>
  </id_info>
  <brief_title>Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients</brief_title>
  <official_title>Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention
      should be continued and to which time a patient with schizophrenia is protected enough, so
      that a withdrawal or reduction of the medication seems appropriate. Relapse is defined as
      primary outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the trial is to evaluate for the first time, how long an antipsychotic
      relapse-prevention should be continued and to which time a patient is protected enough, so
      that a guided withdrawal or reduction of the medication seems appropriate. Relapse is defined
      as primary outcome. We include patients with schizophrenia or schizoaffective disorder in
      remission for at least 3 years under a stable antipsychotic medication.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse</measure>
    <time_frame>Every 2 weeks up to 26 weeks</time_frame>
    <description>The criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:
Score ≥4 (moderate) for at least two of the following PANSS-items :
&quot;Delusions&quot; (P1), &quot;Conceptual disorganisation&quot; (P2), &quot;Halluzinations&quot; (P3), &quot;Mannerisms and posturing&quot; (G5) and &quot;Unusual thought content&quot; (G9) (PANSS; Kay et al., 1987)
Score ≥4 on the &quot;Clinical Global Impression Severity Scale&quot; (CGI-S; Guy, 1976b)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric rehospitalisation</measure>
    <time_frame>Every 2 weeks up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Totalscore of Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline, then every 4 weeks up to 26 weeks</time_frame>
    <description>PANSS-Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of specific adverse effects (open interview)</measure>
    <time_frame>Baseline,then every 4 weeks up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity Scale (CGI-S)</measure>
    <time_frame>Baseline, then every 4 weeks up to 26 weeks</time_frame>
    <description>CGI-I Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Quality of life&quot; measured by the questionnaire &quot;Subjective well-being under neuroleptics scale&quot; (SW-N)</measure>
    <time_frame>Baseline, and after 12 and 26 weeks</time_frame>
    <description>SW-N-Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of occupation</measure>
    <time_frame>Baseline, and after 12 and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal and Social Performance (Personal and Social Performance Scale [PSP])</measure>
    <time_frame>Baseline, and after 12 and 26 weeks</time_frame>
    <description>PSP-Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence/Attitude of patients towards medication (Medication Adherence Rating Scale [MARS])</measure>
    <time_frame>Baseline, and after 12 and 26 weeks</time_frame>
    <description>MARS-Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop-outs total and due to specific reasons</measure>
    <time_frame>Every 2 weeks up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement disorders (Abnormal Involuntary Movement Scale [AIMS])</measure>
    <time_frame>Baseline, and after 12 and 26 weeks</time_frame>
    <description>AIMS-Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>Baseline, and after 12 and 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophrenia and Disorders With Psychotic Features</condition>
  <condition>Schizoaffective Disorders</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (&quot;gradual discontinuation&quot;, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perphenazine</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulpiride</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bromperidol</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zuclopenthixol</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioridazine</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benperidol</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluspirilene</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimozide</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perazine</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluphenazine</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flupentixole</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertindole</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder

          -  The participants have to be in remission for at least 3 years (i.e. no psychiatric
             hospitalisation) under a stable antipsychotic medication. Remission will be measured
             using the remission criteria by Andreasen et al. (2005) Score ≤3 for the items
             concerning psychosis of the &quot;Positive and Negative Syndrom Scale&quot; (PANSS; Kay et al.,
             1987): &quot;Delusions&quot; (P1), &quot;Conceptual disorganisation&quot; (P2), &quot;Halluzinations&quot; (P3),
             &quot;Mannerisms and posturing&quot; (G5) and &quot;Unusual thought content&quot; (G9) and a score ≤3 on
             the &quot;Clinical Global Impression Severity Scale&quot; (CGI-S; Guy, 1976)

          -  Able to give informed consent

        Exclusion Criteria:

          -  Actively suicidal

          -  Serious medical illnesses

          -  Known non-complience concerning the medication

          -  Medication with clozapin

          -  Medication with antidepressants and mood stabilisors that were initiated during the
             last 6 weeks before study enrollment

          -  Patients with substance dependence other than nicotine or caffeine within 6 months
             prior to baseline

          -  Unability to give informed consent

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Leucht, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Dold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Schizophrenia Spectrum and Other Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sertindole</mesh_term>
    <mesh_term>Perphenazine</mesh_term>
    <mesh_term>Fluphenazine</mesh_term>
    <mesh_term>Fluphenazine depot</mesh_term>
    <mesh_term>Fluphenazine enanthate</mesh_term>
    <mesh_term>Pimozide</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
    <mesh_term>Thioridazine</mesh_term>
    <mesh_term>Clopenthixol</mesh_term>
    <mesh_term>Fluspirilene</mesh_term>
    <mesh_term>Benperidol</mesh_term>
    <mesh_term>Perazine</mesh_term>
    <mesh_term>Bromperidol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

